Disrupting Interventions
Wednesday, May 4, 2022
This panel will explore how GCT technology could lead to disruptions in other areas of medicine, including surgery and medical devices, over the next several years. Could cell replacement therapy in diabetes advance enough to reduce the need for diabetes pumps or insulin? Will stem-cell-based methods for regenerating cartilage advance rapidly enough to disrupt the number of patients seeking hip and knee replacements? How is GCT driving innovations in surgical techniques?
- Introducer:
-
- John Fish
-
- Chairman & CEO, Suffolk
- Chair, Brigham and Women’s Hospital
- Moderator:
-
- Robert Higgins, MD
-
- President, Brigham and Women’s Hospital
- Executive Vice President, Mass General Brigham
- Panelists:
-
- Irina Antonijevic, MD, PhD
-
- CMO and Head of R&D, Triplet Therapeutics, Inc.
- Rachel McMinn, PhD
-
- Founder & CEO, Neurogene
- Harith Rajagopalan, MD, PhD
-
- CEO & Co-Founder, Fractyl Health
- Bastiano Sanna, PhD
-
- EVP, Chief of Cell & Gene Therapies and VCGT Site Head, Vertex Pharmaceuticals
- Jeffrey Schweitzer, MD, PhD
-
- Neurosurgeon, MGH
- Assistant Professor of Neurosurgery, HMS